The retrospective investigation of the EORTC 26981/22981 trial demonstrated that the MGMT promoter methylation status is a favorable independent prognostic biomarker in glioblastoma [5, 6]; the NOA-04 trial and the EORTC 26951/26053/22054 trial demonstrated its prognostic value in anaplastic glioma regardless of the histopathological classification and treatment strategy [3, 23, 24]. The gene discussed is MGMT; the disease is grade III glioma.